Search
Fujian Shengdi Pharmaceutical, a Subsidiary of Hengrui Medicine (01276), Receives Approval for Marketing Authorization Application of HRS9531 Injection
2025-09-01 /
Read about 0 minute
Author：小编
Fujian Shengdi Pharmaceutical, a subsidiary of Hengrui Medicine, has received official notification from the National Medical Products Administration that its application for marketing authorization of the HRS9531 Injection has been successfully accepted. This innovative dual agonist drug is designed for long-term weight management in obese adults with a Body Mass Index (BMI) of 28 kg/m² or higher, as well as overweight adults with a BMI of 24 kg/m² or higher who also suffer from at least one weight-related comorbidity. By regulating glucose and lipid metabolism, suppressing appetite, and enhancing insulin sensitivity, HRS9531 Injection effectively improves blood glucose levels and aids in weight reduction.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
